company background image
0YC0 logo

Unity Biotechnology LSE:0YC0 Stock Report

Last Price

US$1.64

Market Cap

US$27.4m

7D

6.2%

1Y

-4.9%

Updated

28 Mar, 2024

Data

Company Financials +

Unity Biotechnology, Inc.

LSE:0YC0 Stock Report

Market Cap: US$27.4m

0YC0 Stock Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

0YC0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Unity Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Unity Biotechnology
Historical stock prices
Current Share PriceUS$1.64
52 Week HighUS$3.79
52 Week LowUS$1.46
Beta0.88
1 Month Change-12.10%
3 Month Change-17.84%
1 Year Change-4.94%
3 Year Change-97.16%
5 Year Change-98.58%
Change since IPO-98.86%

Recent News & Updates

Recent updates

Shareholder Returns

0YC0GB BiotechsGB Market
7D6.2%0.2%2.3%
1Y-4.9%-27.3%2.7%

Return vs Industry: 0YC0 exceeded the UK Biotechs industry which returned -27.3% over the past year.

Return vs Market: 0YC0 underperformed the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0YC0's price volatile compared to industry and market?
0YC0 volatility
0YC0 Average Weekly Movement8.5%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0YC0 has not had significant price volatility in the past 3 months.

Volatility Over Time: 0YC0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200922Anirvan Ghoshhttps://unitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.

Unity Biotechnology, Inc. Fundamentals Summary

How do Unity Biotechnology's earnings and revenue compare to its market cap?
0YC0 fundamental statistics
Market capUS$27.36m
Earnings (TTM)-US$52.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0YC0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$25.20m
Gross Profit-US$25.20m
Other ExpensesUS$27.33m
Earnings-US$52.53m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.13
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 0YC0 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.